StreetAlpha
13F holdings · Q3 2026

Bain Capital Life Sciences Investors

Boston, MA · files as Bain Capital Life Sciences Investors, LLC
Know the moment Bain Capital Life Sciences Investors filesYou follow Bain Capital Life Sciences Investors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1703031

Bain Capital Life Sciences Investors reported 23 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KLRA (17.3%), HTFL (14.8%) and ADRX (9.0%). Compared with Q2 2026, the fund opened new positions in ADRX, TARS and FRNM, added to ALKS and CABA, trimmed HTFL, PHVS and KYTX and sold out of DNTH and UPB.

Latest filing: what Bain Capital Life Sciences Investors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
4 new2 added3 trimmed2 sold outBought about $345M · sold about $255M
New 4
Added 2
Trimmed 3
Sold out 2

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.5B−11.4% vs last quarter
Stocks held234 new · 2 sold out
Top 5 weight56.0%fairly concentrated
Turnover40%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
KLRA
Kailera Therapeutics Inc
$258M17.3%22.6MNo change2 of 8
2
HTFL
Heartflow Inc
$221M14.8%4.4M−4M (−47%)5 of 8
3
ADRX
Adarx Pharmaceuticals Inc
$134M9.0%6.7MNew position1 of 8
4
ALKS
Alkermes PLC
$128M8.6%3.2M+1.2M (+63%)3 of 8
5
NAMS
Newamsterdam Pharma Company
$92.6M6.2%3.8MNo change8 of 8
6
SVRA
Savara Inc
$90.8M6.1%17.6MNo change8 of 8
7
TARS
Tarsus Pharmaceuticals Inc
$86.2M5.8%1.1MNew position1 of 8
8
PHVS
Pharvaris N V
$76.9M5.2%2.5M−200K (−7%)8 of 8
9
SLDB
Solid Biosciences Inc
$70.9M4.8%9.8MNo change8 of 8
10
OLMA
Olema Pharmaceuticals Inc
$61.2M4.1%7.1MNo change8 of 8
🔒 13 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
DNTH
Dianthus Therapeutics Inc
$35.3M362K
UPB
Upstream Bio Inc
$4.2M601K

Reported value

last 8 quarters
$850MQ4 '24
$676MQ1 '25
$799MQ2 '25
$1.5BQ3 '25
$1.3BQ4 '25
$1.1BQ1 '26
$1.7BQ2 '26
$1.5BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Bain Capital Life Sciences Investors 13F FAQ

What does Bain Capital Life Sciences Investors own?

Bain Capital Life Sciences Investors reported 23 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KLRA (17.3%), HTFL (14.8%) and ADRX (9.0%). The table above lists every position in the filing (the top 10 without an account).

What did Bain Capital Life Sciences Investors buy and sell in Q3 2026?

Compared with Q2 2026: 4 new positions, 2 added to, 3 trimmed and 2 sold out. New positions include ADRX, TARS and FRNM. It sold all of DNTH and UPB.

When will Bain Capital Life Sciences Investors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Bain Capital Life Sciences Investors's portfolio worth?

The Q3 2026 filing reports $1.5B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.